Updated: 6 days ago
Telemedicine and AI diagnostics are in their infancy but could offer lower cost solutions to billions in developing markets. Therapies developed in EM also promise better outcomes and lower costs
Telemedicine (remote healthcare over the internet) and AI-based diagnostics and therapies remain in the early stages around the world
However, they promise to offer much lower cost solutions to extend health care coverage to huge numbers of people in the developing world
Meanwhile, world class innovation in areas such as drug development and medical devices continues around the emerging world
These offer the promise of further cost savings and better outcomes for patients both in emerging markets and even in the developed world
Historically, healthcare systems in developing markets have been inefficient and costly but this is changing with the adoption of telemedicine, national reimbursement systems, advancements in drug development and novel approaches to cost management. Remarkably, many emerging markets now have life expectancy and infant mortality rates approaching those of some parts of the developed world.
China’s Ping An, Alibaba and Tencent all have vested stakes in the space of telemedicine to develop and improve diagnosis and doctor/patient optimization, efficient drug delivery, and remote human doctor communication. Indonesia’s premier provider, Halodoc, has an edge in logistics aiding natural disaster victims and enhancing safety. Capital injection to this thriving industry can increase efficient delivery of healthcare services and doctor penetration.
Prince Street expects many investment opportunities across the developing world to emerge from these disruptive trends.